Company: PACB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001299130-25-000156
Chunk: 11

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 11
---
5

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) Six Months Ended June 30,(In thousands)20252024Cash flows from operating activitiesNet loss$(468,005)$(251,497)Adjustments to reconcile net loss to net cash used in operating activitiesDepreciation 7,790 6,739 Amortization of intangible assets367,409 13,706 Amortization of right-of-use assets2,162 5,858 Share-based compensation expense21,096 36,744 Impairment charges15,000 93,200 Accretion of discount and amortization of premium on marketable securities, net(2,982)(7,572)Change in the estimated fair value of contingent consideration(18,700)(70)Inventory provision8,542 3,922 Deferred income taxes(546)— Other1,059 702 Changes in assets and liabilities Accounts receivable, net(4,733)4,182 Inventory, net(3,868)(16,767)Prepaid expenses and other assets 6,809 3,559 Accounts payable (505)3,390 Accrued expenses (2,407)(23,250)Deferred revenue 808 3,046 Operating lease liabilities(1,730)(4,748)Other liabilities (632)(1,089)Net cash used in operating activities (73,433)(129,945)Cash flows from investing activitiesPurchases of property and equipment (1,939)(5,358)Purchases of intangible assets(5,000)— Purchases of investments (117,992)(303,564)Maturities of investments 195,448 351,623 Net cash provided by investing activities 70,517 42,701 Cash flows from financing activitiesProceeds from issuance of common stock from equity plans1,959 6,891 Notes payable principal payoff— (490)Net cash provided by financing activities 1,959 6,401 Net decrease in cash, cash equivalents, and restricted cash(957)(80,843)Cash, cash equivalents, and restricted cash at beginning of period 57,592 182,633 Cash, cash equivalents, and restricted cash at end of period $56,635 $101,790 Cash and cash equivalents at end of period